Syntocinon
Phase 2UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Frontotemporal Dementia
Conditions
Frontotemporal Dementia
Trial Timeline
Jan 31, 2018 → Dec 31, 2024
NCT ID
NCT03260920About Syntocinon
Syntocinon is a phase 2 stage product being developed by Brain Biotech for Frontotemporal Dementia. The current trial status is unknown. This product is registered under clinical trial identifier NCT03260920. Target conditions include Frontotemporal Dementia.
What happened to similar drugs?
0 of 2 similar drugs in Frontotemporal Dementia were approved
Approved (0) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
12
Activity
4
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03260920 | Phase 2 | UNKNOWN |
Competing Products
7 competing products in Frontotemporal Dementia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AL001 + Placebo + Open label - AL001 | Alector | Phase 3 | 22 |
| AL001 | Alector | Phase 2 | 25 |
| LY3884963 + Methylprednisolone + Optional Sirolimus + Optional Prednisone | Eli Lilly | Phase 1/2 | 36 |
| galantamine hydrobromide | Johnson & Johnson | Phase 2 | 35 |
| memantine hydrochloride | Lundbeck | Phase 3 | 37 |
| DNL593 + Placebo | Denali Therapeutics | Phase 1/2 | 30 |
| PBFT02 | Passage Bio | Phase 1/2 | 29 |